The 9th China Orthopedics, Biomaterials and Smart Healthcare Industry Investment Summit Concludes Successfully in Changzhou
Co-hosted by CHC Medical Consulting and Changzhou West Taihu Lake Science and Technology Industrial Park“The 9th China Orthopedics, Biomaterials and Smart Healthcare Industry Investment Summit” concluded in Changzhou on October 13, 2021.Nearly 300 distinguished guests from government agencies, academic institutions, innovative enterprises, and the investment community attended the summit. These industry leaders gathered to engage in in-depth exploration and reflection on current hot topics and key issues in orthopedics both domestically and internationally, with the aim of jointly fostering the robust development of China’s orthopedic industry. The event featured vibrant interactions between speakers and the audience, creating a lively and enthusiastic atmosphere.
Dr. Nie Hongxin, Conference Chair, Managing Partner of Shanlan Capital, and Honorary Chairman of the Surgical Implants Professional Committee of the China Medical Device Industry Association, and Mr. Li Desen, Member of the Standing Committee of the Wujin District Committee of the Communist Party of China in Changzhou City, Minister of the United Front Work Department, and Deputy District Mayor, jointly delivered the opening remarks, officially kicking off the summit.
Nie Hongxin, Conference Chair; Managing Partner at Shanlan Capital; Honorary Chairman of the Surgical Implant Professional Committee of the China Medical Device Industry Association
As a key industry stakeholder, Dr. Nie Hongxin noted in her opening remarks that the orthopedics sector has undergone profound transformation and disruption this year under the influence of national policies. From the perspectives of both entrepreneurs and investors in the primary and secondary markets, the industry has entered a critical phase. She expressed hope that this summit would bring fresh directions to discussions on the development of the orthopedics industry from diverse angles. In her subsequent presentation, Dr. Nie shared insights across four dimensions: future trends in the orthopedics industry, the issuance and adjustment of laws and regulations, technological innovation by enterprises, and reflections on orthopedic investments. She emphasized that gaining an in-depth understanding of the core elements driving development in the orthopedics field is crucial, noting that many gains stem from monetizing cognitive insights and that trends often require patience. Therefore, many outstanding companies have essentially “endured” their way to success.
Li Desen, Member of the Standing Committee of the Wujin District Committee of the Communist Party of China in Changzhou City, Minister of the United Front Work Department, and Deputy District Mayor of the People's Government
District Mayor Li Desen stated that Wujin District in Changzhou boasts superior geographical conditions, a solid industrial foundation, and a favorable entrepreneurial atmosphere. The high-end medical industry is a key focus for the park, with significant investments being made in innovative medical devices, insured medical treatments, and smart healthcare. The district is committed to fostering a first-class development ecosystem for the medical and health industry in the Yangtze River Delta, aiming to build an internationally renowned medical innovation hub recognized across the Yangtze River Delta and globally. Furthermore, the lofty vision of “Healthy China 2030” will undoubtedly be realized as scheduled.
Zhao Jinzhong, Director of the Department of Sports Medicine, Shanghai Sixth People's Hospital
Professor Zhao Jinzhong at"Frontier Technologies in Sports Medicine and Their Clinical Applications in China"The report highlights that the development of kinesiology has primarily benefited from two key factors: 1) National strategy, with sports medicine covering a broad spectrum and its developmental trends in China being evident in recent years; 2) Clinical technological innovations in sports medicine are leading both domestically and internationally. Furthermore, from the perspective of clinicians, regenerative sports medicine represents an important direction for development, with the aim of leveraging regenerative medicine to enable patients to achieve structural repair and functional recovery as rapidly as possible.
Wang Binbin, Director and CEO of Beijing Medical Robot Industry Innovation Center
Ms. Wang Binbin, with"The Current Status and Future of Intelligent Orthopedics and Orthopedic Surgical Robots"Centered on this theme, she articulated her perspective: She believes that technological advancements have spurred the development of the entire orthopedic industry. Regarding orthopedic robots, although they have entered the era of intelligent assistance, they remain a key focus for ongoing industry efforts. She expressed hope that integrating 5G communication technology with orthopedic robotic technology will empower and accelerate the development of smart healthcare. Finally, she shared Tinavi’s insights as a leading enterprise in orthopedic robotics, outlining its understanding of the industry and its future strategic priorities.
Wang Zaicun, Chief Analyst of the Medical Devices and Services Sector at the Research & Development Department of China Securities Co., Ltd.
The hottest topic recently has been “volume-based procurement (VBP).” In this context, Mr. Wang Zaicun shared insights on the strategic transformation directions for medical device companies. Key points included: 1) Opportunities and challenges amid policy changes; 2) Strategic transformation of listed companies under the VBP framework. He emphasized that, in light of varying price reduction rates across different regions, it is essential to grasp the core essence of VBP. Finally, he provided a detailed analysis of the differences, advantages, and disadvantages between national-level and local-level volume-based procurement.
Hong Youliang, Professor at the National Engineering Research Center for Biomaterials, Sichuan University
Professor Hong Youliang Delivers a Report"Engineered Biomaterials for In Situ Bone Regeneration,"He believes that overcoming challenges and establishing an environment conducive to in situ bone regeneration is the most pressing issue at present. As a critical component of the orthopedic industry, biomaterials must undergo continuous innovation and address inherent material limitations; these efforts are crucial for breaking through the current impasse in achieving domestic substitution with Chinese-made products.
Based on professional data surveys and industry research, CHC Medical Consulting, in collaboration with LeadLeo (Shanghai) Research Institute, jointly launches the “"White Paper on Research of China's Orthopedic Device Industry"Officially released. The book provides an in-depth analysis of the current state and future development trends of China's orthopedic device industry.
Sun Rong, Senior Analyst in the Healthcare Industry at LeadLeo Research Institute
Moderator:
Lu Meijiao, Deputy General Manager and Board Secretary of Zhenghai Biotechnology
Guest Speakers:
Yao Jianqing, Chairman of Jiaoying Medical Devices (Shanghai) Co., Ltd.
General Manager, Yabonisi Medical Technology (Suzhou) Co., Ltd.
Sun Yang, Founder and Chairman of Lixin Science
Yang Daning, General Manager of Shangrong Bio
Hong Youliang, Professor at the National Engineering Research Center for Biomaterials, Sichuan University
Ms. Lu Meijiao expects all products to better align with clinical needs, adhere to national policies, and facilitate their translation into practice. Meanwhile, as market homogenization intensifies and a large number of products included in centralized volume-based procurement emerge, urgent solutions are needed to achieve breakthrough innovation and identify its key drivers.
Mr. Yao Jianqing believes that, beyond biomaterials, there are still many untapped blue-ocean opportunities in the field of artificial joints.
Mr. Sun Yang has recognized the robust market demand for regenerative medicine, which necessitates innovation in materials to truly achieve global innovation in China’s medical device industry.
Mr. Yang Daning believes that the vast majority of domestic orthopedic companies are engaged in back-end processing, unable to achieve significant breakthroughs and innovations in raw materials. He hopes to break monopolies in certain niche sectors in the future, enabling innovative Chinese international medical devices to go further and perform better.
Professor Hong Youliang has profound insights into the research, development, application, and understanding of raw materials for orthopedics. He believes that, regarding raw materials, we should rely on chemical methods and technological advancements, and the breakthroughs needed for source innovation warrant deep reflection from all stakeholders.
Niu Ming, Deputy Director of the Changzhou Xitaihu International Innovation Center for Medical Technology
Director Niu Ming provided the attending guests with a detailed introduction to the Changzhou West Taihu Lake Science and Technology Industrial Park, highlighting the numerous explorations and developmental initiatives undertaken by the park to support enterprise growth. The presentation primarily covered the following five aspects: 1. Changzhou’s impressive statistical achievements; 2. Quality-driven acceleration and expansion of high-end industrial layout in Changzhou; 3. A mindset geared toward industrial innovation; 4. Unique platform advantages; 5. Recent development trends of the park and its industrial sectors.
Richard Wang, Of Counsel, Intellectual Property,Beijing office of Wilson Sonsini Goodrich & Rosati
From the perspective of intellectual property patents, Mr. Richard Wang provided a comprehensive analysis of the overall medical device industry and conducted a detailed examination of litigation trends involving domestic medical devices in China. Finally, he urged all stakeholders to place greater emphasis on intellectual property issues, highlighting their critical importance.
Dou Yuandong, R&D Director at Huamu Medical
Mr. Dou Yuandong shared insights ranging from the popularization of the concept of absorbable materials to the current application status of orthopedic consumable implants, as well as typical foreign products and the underlying cutting-edge technologies and trends. As an innovative enterprise, Huamu Medical leverages innovation as its driving force to develop proprietary degradable biomaterials and a diverse portfolio of implant products. In the future, Huamu Medical will expand into more fields, replacing traditional implants with those made from absorbable materials.
Zhang Yu, CEO of Xinrong Bolt Medical
Ms. Zhang Yu shared her perspectives and reflections on the post-volume-based procurement (VBP) era. She emphasized that delivering value is a critical consideration worthy of industry-wide reflection. Within the broader context of VBP, it is essential to develop a clear understanding of innovative products. As for competition across the entire healthcare industry, it is fundamentally returning to its core essence, which constitutes the overarching strategic logic.
Zhang Yiling, Chairman and CEO of Changmugu
For orthopedic surgeries, the formulation of a precise preoperative surgical plan is critical to the success of the procedure. Mr. Zhang Yiling stated that digital and intelligent robotics will become a highly significant development direction for Changmugu over the next 5–10 years. As artificial intelligence becomes increasingly widespread, AI-integrated surgical robots have become a top priority in current industry research. Finally, he provided an overview and illustrative examples of the AIKNEE artificial intelligence system.
Moderator:Wang Haijiao, Executive Partner at GTJA Investment;Speakers:Huang Zhijun, General Manager of Laparoscopic Robot Company; Hu Lei, Chairman of Zhuozheng Robotics Co., Ltd.; Hu Shanyun, Founder and Chairman of Jiesibai'er; Dong Chao, Co-founder and CEO of Yingwei Medical; Jia Xu, Investment Director at Legend Capital
Mr. Huang Zhijun shared his perspective, noting that due to the sluggish performance of the Hong Kong stock market, companies are adopting a more long-term outlook in their strategic considerations. He believes that leveraging capital to accumulate resources, drive growth, and deliver rapid benefits represents a distinctly different approach worthy of deep reflection.
Mr. Hu Lei believes that for entrepreneurial companies in the orthopedic field, seizing opportunities is crucial. Given the differing requirements between preoperative positioning robots and intraoperative augmented-navigation systems, a balanced approach combining rigidity with flexibility is essential. In the future, minimally invasive data acquisition will become a more prominent trend.
Mr. Hu Shanyun stated that 5G presents an opportunity for the industry. However, from a product development perspective, significant gaps remain between domestic and international surgical robots. Therefore, in the future, particularly in the development of robotics, we need to make greater efforts in the areas of artificial intelligence and intelligent decision-making.
Mr. Dong Chao believes that 5G is closely related to our data, especially in the healthcare industry, which requires in-depth discussion. At the same time, it must be integrated with and adapted to market demands.
“In the case of orthopedic surgical assistance systems, the focus is more on the composition of procedural steps to assist surgeons in completing orthopedic procedures; this represents our internal understanding and definition,” stated Mr. Jia Xu. Volume-based procurement is not merely about subtraction; capital markets should adjust their overall strategies in accordance with the laws of industrial development.
Mr. Wang Haijiao concluded: “Against the backdrop of the 5G era and centralized volume-based procurement under the national medical insurance scheme, the review process for listings on the STAR Market has become increasingly stringent, presenting both opportunities and challenges for international development.”
Moderator:Yi Lin, Managing Director of Defu Capital;Featured Speakers:Bai Yanhui, Director of Business Development, Greater China, DSM Biomedical; Zhang Mei, Chairman of Wanjie Tianyuan; Hu Xuyu, Partner at Jifeng Capital; Zeng Sheng, Founder and CEO of Susheng Biotech
Mr. Bai Yanhui stated that, as an implant materials company, it is DSM’s mission to accelerate and assist domestic sports medicine enterprises in achieving leapfrog development, thereby catching up with top-tier international companies more rapidly. He offered the following recommendations to industry participants: 1. Pursue innovation while considering global intellectual property layout; 2. Maintain a profound reverence for implants, avoid short-sighted pursuits of quick success, and refrain from engaging in non-compliant practices; 3. Conduct global pilot projects and possess a global perspective.
Ms. Zhang Mei stated that the sports medicine sector is currently dominated by imported brands, while domestic enterprises hold a relatively small market share and are comparatively young in their development. To break through this competitive landscape and secure a foothold, domestic companies should prioritize the integration of industry, academia, research, and clinical application. This involves fostering collaboration among enterprises, research institutions, and clinical practitioners, ensuring substantial investment in research and development, withstanding market scrutiny on the sales front, and executing effective brand promotion and market education.
Mr. Hu Xuyu is optimistic about the development of the sports medicine industry. He believes that the core of patent layout in sports medicine lies in whether technological capabilities can compete with international multinational corporations, and whether the patent strategy can keep pace throughout the commercialization process.
Mr. Zeng Sheng emphasized the importance of innovation and staying true to the original mission. He noted that while everyone recognizes innovation as the right path, it is inherently challenging. Nevertheless, companies must rise to the occasion, striving to catch up and surpass competitors by starting from the fundamentals—ranging from materials science to product design. Beyond economic objectives, the core commitment to addressing clinical needs with superior products and benefiting a broader population serves as a more powerful impetus for enterprises to develop higher-quality materials and products.
Ms. Yi Lin, an investor, stated that she looks forward to seeing companies in the industry become increasingly competitive by staying committed to innovation and strengthening their foundational operations. She also expressed her hope to leverage capital to support these enterprises in achieving better growth and expanding globally—a scenario that healthcare investors are particularly eager to witness.